The present invention relates to methods for treating
cell proliferation disorders comprising (1) administering to the subject at least one activatable pharmaceutical agent that is capable of activation by a simultaneous
two photon absorption event and of effecting a predetermined cellular change when activated, (2) administering at least one plasmonics-
active agent to the subject, and (3) applying an
initiation energy from an
initiation energy source to the subject, wherein the plasmonics-
active agent enhances or modifies the applied
initiation energy, such that the enhanced or modified initiation energy activates the activatable pharmaceutical agent by the simultaneous
two photon absorption event in situ, thus causing the predetermined cellular change to occur, wherein said predetermined cellular change treats the
cell proliferation
related disorder, and the use of plasmonics enhanced photospectral therapy (PEPST) and exiton-
plasmon enhanced phototherapy (EPEP) in the treatment of various
cell proliferation disorders, and the PEPST and EPEP agents and probes